Compare COO & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COO | EVR |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 14.4B |
| IPO Year | 1994 | 2006 |
| Metric | COO | EVR |
|---|---|---|
| Price | $71.10 | $274.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $90.18 | ★ $344.00 |
| AVG Volume (30 Days) | ★ 1.8M | 591.7K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | N/A | ★ 54.74 |
| EPS | 0.66 | ★ 14.05 |
| Revenue | $2,532,800,000.00 | ★ $3,880,084,000.00 |
| Revenue This Year | $6.61 | $22.35 |
| Revenue Next Year | $5.36 | $13.37 |
| P/E Ratio | $111.71 | ★ $20.53 |
| Revenue Growth | 18.41 | ★ 29.49 |
| 52 Week Low | $61.78 | $148.63 |
| 52 Week High | $89.83 | $388.71 |
| Indicator | COO | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 20.01 | 30.21 |
| Support Level | $67.78 | $238.96 |
| Resistance Level | $75.25 | $320.26 |
| Average True Range (ATR) | 2.09 | 13.84 |
| MACD | -1.35 | -2.79 |
| Stochastic Oscillator | 1.86 | 2.28 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.